Tuesday, Javelin Pharmaceuticals Inc. (JAV) said its third-quarter net loss attributable to common stockholders narrowed to $6.8 million or $0.11 per share from $10.9 million or $0.18 per share in the prior year period. On average, 3 analysts polled by Thomson Reuters expected the company to report a loss of $0.10 per share for the quarter.
Total revenues for the quarter rose to $1.13 million from $0.36 million in the comparable period. Analysts estimated revenues of $920.00 thousand for the quarter.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.